CANCER ALLIANCE PUBLISHES IMPORTANT NEW STUDY ON BREAST CANCER AND TRASTUZUMAB ACCESS IN SOUTH AFRICA

Tobeka Daki Trastuzumab Access CampaignThe Cancer Alliance today publishes an important new study BREAST CANCER and HER2+ BREAST CANCER WITH A LOOK AT TRASTUZUMAB ACCESS IN SOUTH AFRICA.

Breast cancer is the most common cancer in South Africa. It is also the second highest cancer killer of our women. At least 1 in 27 women will be diagnosed with breast cancer in their lifetime. Of these 26% will be diagnosed with HER2+ breast cancer. Adjuvant treatment (Treatment that is given in addition to the primary (initial) treatment to maximise its effectiveness) is provided in the form of trastuzumab.

To date only the originator trastuzumab Herceptin® and Herclon® are available in South Africa. The originator product Herceptin® is available in the private sector but remains unaffordable for the majority of women. Secondary patents for this medicine could block the entry of competitor products until 2026.

Click here to read more and download the full report.

Related Articles

Related

Public Voices Rise

The Cancer Alliance represented by SECTION27 returned to court today in the matter of Cancer Alliance v the MEC for Health, Gauteng and 10 others. Today’s proceedings concerned an application for leave to appeal instituted by the provincial health respondents in...

read more

Justice Delivered

SECTION27 and Cancer Alliance welcome Court judgment on the provision of lifesaving radiation oncology treatment for thousands of cancer patients SECTION27 and Cancer Alliance, welcome the judgment handed down today by the Johannesburg High Court in the...

read more

CELGENE FLAGGED

For overpricing bone marrow cancer drug The Competition Commission has referred for prosecution to the Competition Tribunal (“Tribunal”), international drug manufacturer Celgene Corporation (“Celgene Corp”) and its subsidiary Celgene Logistics S.a.r.l (“Celgene...

read more